← Leaderboards
Brian Geiss
Colorado State University
$5,314,620
Attributed
$6,821,853
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,821,853 · 7
By mechanism
R01$4,037,132 · 3
U54$1,395,524 · 1
R61$908,637 · 1
R21$407,060 · 1
R03$73,500 · 1
Top collaborators
- David S Dandy4 shared
- Charles S Henry4 shared
- Jeffrey Wilusz1 shared
Most similar at Colorado State University
Same institution · by research overlap
- Charles S Henry$4,415,902
- Raymond Paul Goodrich$4,057,902
- Joaquin M. Espinosa$27,103,546
- Mary Jackson$25,157,631
- William Schountz$299,998
Others in their field
Top investigators on “Viral”
- Lawrence Corey · Fred Hutchinson Cancer Center$466,994,927
- David Heimbrook · Leidos Biomedical Research, Inc.$366,090,791
- Daniel R Kuritzkes · Brigham And Women'S Hospital$267,074,199
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$252,763,614
- Judith S. Currier · University Of California Los Angeles$185,434,785
- Constance Ann Benson · University Of California, San Diego$165,517,633
Research focus
ViralInfectionBaseViral RnaVirusRna CapsBiochemicalAntiviral AgentsEnzymesProteinsGuanosine TriphosphateStructureViral GenomeFlavivirusTranslationsCulicidaeFamilyDesignMorbidity - Disease RatePathogenGuanosineCellsGuanylyltransferaseFlavivirus Infections
Grant awards (20)
Development of a robust HIV-1 diagnostic system (HIV-eCaDI) for at-home testing$444,760
R61 · FY2025 · AI · contact PI
Development of a robust HIV-1 diagnostic system (HIV-eCaDI) for at-home testing$463,877
R61 · FY2024 · AI · contact PI
Mechanism of Flavivirus RNA Capping$374,993
R01 · FY2022 · AI · contact PI
A SARS-CoV-2 NFC ePAD Biosensor$58,053
R01 · FY2022 · EB
A SARS-CoV-2 NFC ePAD Biosensor$988,864
R01 · FY2021 · EB
Mechanism of Flavivirus RNA Capping$374,993
R01 · FY2021 · AI · contact PI
Mechanisms and functional implications of SARS-CoV-2 mRNA capping and modification.$407,060
R21 · FY2020 · AI
Mechanism of Flavivirus RNA Capping$374,993
R01 · FY2020 · AI · contact PI
Mechanism of Flavivirus RNA Capping$374,993
R01 · FY2019 · AI · contact PI
Mechanism of Flavivirus RNA Capping$374,993
R01 · FY2018 · AI · contact PI
A High-Throughput Screen for Antiviral Inhibitors of the Alphavirus RNA Capping Enzyme$371,750
R01 · FY2017 · AI · contact PI
A High-Throughput Screen for Antiviral Inhibitors of the Alphavirus RNA Capping Enzyme$371,750
R01 · FY2016 · AI · contact PI
A High-Throughput Screen for Antiviral Inhibitors of the Alphavirus RNA Capping Enzyme$371,750
R01 · FY2015 · AI · contact PI
Development and optimization of novel anti -flavivirus compounds$277,815
U54 · FY2013 · AI · contact PI
Development and optimization of novel anti -flavivirus compounds$283,462
U54 · FY2012 · AI · contact PI
A High-Throughput Assay for Probes of the Flavivirus RNA Guanylyltransferase$36,750
R03 · FY2012 · MH · contact PI
Development and optimization of novel anti -flavivirus compounds$270,249
U54 · FY2011 · AI · contact PI
A High-Throughput Assay for Probes of the Flavivirus RNA Guanylyltransferase$36,750
R03 · FY2011 · MH · contact PI
Development and optimization of novel anti -flavivirus compounds$302,342
U54 · FY2010 · AI · contact PI
Development and optimization of novel anti -flavivirus compounds$261,656
U54 · FY2009 · AI · contact PI